Home・Stock List・Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Closed

SectorHealthcare

145.87 0.08

Buy Sell

Overview

Share price change

24h

Current

Min

143.99

Max

147

Key metrics
By Trading Economics
Income	-82M 3.8M
Sales	49M 56M
P/E Sector Avg	131.197 68.51
EPS	0.05
Profit margin	6.711
Employees	131
EBITDA	46M 2.7M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+1.25% upside

Dividends
By Acuity
Next Earnings	11 Aug 2026

Market Stats
By TradingEconomics
Market Cap	2.1B 8.5B
Previous open	145.79
Previous close	145.87

News Sentiment

By Acuity

34%

66%

96 / 340 Healthcare

Protagonist Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Aug 2026, 19:52 UTC

Social Media

News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5 Aug 2026, 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4 Aug 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3 Aug 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 Jul 2026, 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 Jul 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 Jul 2026, 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 Jul 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 Jul 2026, 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 Jul 2026, 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 Jul 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 Jul 2026, 19:41 UTC

News

Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Peer Comparison

Price change

Protagonist Therapeutics Inc Forecast

Price Target

By TipRanks

1.25% upside

12 Months Forecast

Average 148 USD 1.25%

High 175 USD

Low 110 USD

Based on 10 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Protagonist Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

96 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.